Trial Profile
An Expanded Treatment Protocol of Panobinostat (LBH589) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma Who Have Had at Least One Prior Line of Therapy
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 20 Aug 2019
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Bortezomib; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Expanded access
- Acronyms PANEX
- Sponsors Novartis Pharmaceuticals
- 28 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 04 Aug 2014 New trial record